CHICAGO--(BUSINESS WIRE)--Health care professionals, patients and payors are increasingly seeking safe first-line therapeutic alternatives that provide demonstrated efficacy without drug-related side effects. Neurowave Medical Technologies™ (NMT), a leading neuroscience company that develops and commercializes drug-free, non-invasive transdermal devices based on a patented and proprietary neuromodulation therapeutic technology platform, today announced an expanded focus of its corporate direction, which will broaden its market and growth potential.
Grounded both in biomedical devices and pharmaceutical science, NMT’s first FDA-cleared clinical products will address a broad range of solutions for patients experiencing emesis, commonly known as nausea and vomiting, as a result of acute and chronic clinical conditions. The company’s product development platform, based on transdermal neuromodulation technology, will be leveraged for a wide variety of emesis indications, including post-operative nausea, cancer treatment, pregnancy and motion sickness, among others. In addition, NMT will be pursuing other indications in numerous central nervous system-based disease states that are well-suited to this unique delivery platform.
“Our mission is to become the recognized global leader in transdermal neuromodulation therapeutic medical devices that produce the same if not more effective clinical results than drug therapy,” said Farhan Hussain, CEO of Neurowave Medical Technologies. “The market is ripe for alternatives to drug therapies from a patient use, safety, cost, and clinical outcomes standpoint. NMT is in a great position to distribute our anti-emetic transdermal products in each clinical market segment through its own sales and marketing teams, and by working with key partners and distributors for the retail, clinical and international marketplaces.”
NMT recently launched Reletex™, a new transdermal neuromodulation device for treating post-operative nausea (www.reletex.com), one of the most widespread yet under-reported problems after surgery that affects almost every surgery patient. Recent studies suggest that despite currently available medications, patients consider post-operative nausea among the most significant issues, even more so than pain.
NMT has swiftly built a highly capable and experienced commercial organization to drive rapid success in the Post-Surgical market space. In addition, the company has established a leadership team of industry veterans to provide strategic and tactical capability across the total clinical platform.
Farhan Hussain is President and CEO of Neurowave Medical Technologies. Prior to NMT, Mr. Hussain was a founding partner of The Gulfcare Group (GCG). GCG was created to leverage extensive knowledge and relationships within the United States and the Gulf Region to explore, create, link and grow business ventures in ways which are beneficial to and profitable for both regions. Prior to founding GCG, Mr. Hussain served in various sales and business development roles with Johnson & Johnson.
Chris Littel has served as the Neurowave Medical Vice President of Marketing since April 2010. Prior to joining NMT, Mr. Littel spent over 15 years with Ethicon Endo-Surgery, a high growth medical device franchise within Johnson & Johnson, and 16 years in the United States Army. Mr. Littel has held numerous management positions in his careers, ranging from Operations, Business Development, Research and Development, and Marketing.
Mateen Husami has served as the Vice President of Legal/Licensing for Neurowave Medical since June 2008, and is responsible for all of legal and licensing matters for the Company. Before joining Neurowave, Mr. Husami was Senior Counsel in the Corporate Legal and International Legal Departments at Abbott Laboratories. Prior to joining Abbott, Mr. Husami was an attorney at the law firms of DLA Piper Marbury and McGuire Woods where he practiced corporate law. A certified public accountant, Mr. Husami began his career as an auditor with Price Waterhouse.
Jeffrey A. Whitnell has served as the Vice President of Finance for Neurowave Medical since June 2010, and is responsible for all of the general accounting, financial reporting and treasury activities for the Company. Before joining Neurowave, Mr. Whitnell was the Chief Financial Officer and Senior Vice President of Finance with Akorn, Inc. (NASDAQ: AKRX), a specialty pharmaceutical company engaged in the development, manufacture and marketing of multi-source and branded pharmaceutical products.
Mark Rogozinski joined Neurowave Medical as Executive Director of Health Care Economics and Strategy in July, 2010 after working for Managed Care Agency Hobart Forte in NYC. There, he was the Director of Strategic Services. Prior to Hobart Forte, Mr. Rogozinski had 20 years of experience working in key medical device firms, including Ethicon Endo-Surgery (JNJ), VNUS Medical Technologies, and Medtronic Neurological. Prior to that Mark held a variety of positions at Aetna Health Plans and Metra-Health (formerly The Travelers) in contracting, and account management.
About Neurowave Medical Technologies
Neurowave Medical TechnologiesTM (NMT) is a rapidly growing, privately held Chicago-based neuroscience company that develops and manufactures transdermal neuromodulation devices for the treatment of a wide range of acute and chronic clinical conditions. Using its patented and proprietary neuromodulation technology platform, NMT’s mission is to take the proven science of neurostimulation and offer non-drug “first line” therapeutic solutions that are on par with the efficacy of “gold standard” pharmaceuticals, but superior in terms of safety profile, side effects, patient compliance, and ease of use. NMT commercializes products via an internal sales force, out–licensing and distribution to various marketing partners worldwide. For company information, visit www.neurowavemedical.com.